Kazia Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Kazia Therapeutics (KZIA).

Price Target Range — 9 Quarters

Analyst Consensus — 7 Analysts

7Buy

Consensus RatingBuy# Analysts7Avg. Consensus PT$26Upside to Avg. PT+231.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 20, 2026	Leerink Partners	Andrew Berens	Initiate	Outperform	$30
Sep 10, 2026	BTIG	Kambiz Yazdi	Maintained	Buy	$40
Sep 1, 2026	BTIG	Kambiz Yazdi	PT Raise	Buy	$34→$40
Aug 13, 2026	Canaccord Genuity	John Newman	Initiate	Buy	$29
Jul 15, 2026	BTIG	Kambiz Yazdi	Maintained	Buy	$34
Jul 1, 2026	BTIG	Kambiz Yazdi	Initiate	Buy	$34
Jun 11, 2026	Lake Street	—	Initiate	Buy	$32
Apr 15, 2026	Laidlaw & Co.	Yale Jen	Initiate	Buy	$25
Jan 28, 2026	HC Wainwright & Co.	Sean Lee	Maintained	Buy	$18
Dec 12, 2025	HC Wainwright & Co.	Sean Lee	PT Raise	Buy	$13→$18
Oct 2, 2025	Maxim Group	Naz Rahman	PT Raise	Buy	$15→$20
Jul 10, 2025	HC Wainwright & Co.	Sean Lee	PT Raise	Buy	$2→$13
Jun 11, 2025	Maxim Group	Jason McCarthy	Maintained	Buy	$15
Feb 6, 2025	Maxim Group	Jason McCarthy	Initiate	Buy	$3
Jul 12, 2024	HC Wainwright & Co.	Sean Lee	Maintained	Buy	$2

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Leerink Partners Initiates Coverage On Kazia Therapeutics with Outperform Rating, Announces Price Target of $30

Leerink Partners analyst Andrew Berens initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Outperform rating and announces Price Target of $30.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Kazia Therapeutics, Maintains $40 Price Target

BTIG analyst Kambiz Yazdi reiterates Kazia Therapeutics (NASDAQ:KZIA) with a Buy and maintains $40 price target.

Benzinga Newsdesk

PRO
BTIG Maintains Buy on Kazia Therapeutics, Raises Price Target to $40

BTIG analyst Kambiz Yazdi maintains Kazia Therapeutics (NASDAQ:KZIA) with a Buy and raises the price target from $34 to $40.

Benzinga Newsdesk

PRO
Canaccord Genuity Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $29

Canaccord Genuity analyst John Newman initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces Price Target of $29.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Kazia Therapeutics, Maintains $34 Price Target

BTIG analyst Kambiz Yazdi reiterates Kazia Therapeutics (NASDAQ:KZIA) with a Buy and maintains $34 price target.

Benzinga Newsdesk

PRO
BTIG Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $34

BTIG analyst Kambiz Yazdi initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces Price Target of $34.

Benzinga Newsdesk

Kazia Therapeutics Ltd

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Kazia Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Leerink Partners Initiates Coverage On Kazia Therapeutics with Outperform Rating, Announces Price Target of $30

PRO
BTIG Reiterates Buy on Kazia Therapeutics, Maintains $40 Price Target

PRO
BTIG Maintains Buy on Kazia Therapeutics, Raises Price Target to $40

PRO
Canaccord Genuity Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $29

PRO
BTIG Reiterates Buy on Kazia Therapeutics, Maintains $34 Price Target

PRO
BTIG Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $34

People Also Watch

People Also Watch

Kazia Therapeutics Ltd

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Kazia Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROLeerink Partners Initiates Coverage On Kazia Therapeutics with Outperform Rating, Announces Price Target of $30

PROBTIG Reiterates Buy on Kazia Therapeutics, Maintains $40 Price Target

PROBTIG Maintains Buy on Kazia Therapeutics, Raises Price Target to $40

PROCanaccord Genuity Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $29

PROBTIG Reiterates Buy on Kazia Therapeutics, Maintains $34 Price Target

PROBTIG Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $34

People Also Watch

People Also Watch

PRO
Leerink Partners Initiates Coverage On Kazia Therapeutics with Outperform Rating, Announces Price Target of $30

PRO
BTIG Reiterates Buy on Kazia Therapeutics, Maintains $40 Price Target

PRO
BTIG Maintains Buy on Kazia Therapeutics, Raises Price Target to $40

PRO
Canaccord Genuity Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $29

PRO
BTIG Reiterates Buy on Kazia Therapeutics, Maintains $34 Price Target

PRO
BTIG Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $34